Mifepristone: The debate continues
Mifepristone: The debate continues
Much debate continues over the appropriateness of the Food and Drug Administration’s (FDA) decision to approve mifepristone (Mifeprex), formerly known as RU486, for medical abortions.
When mifepristone was first approved, the American Medical Women’s Association (AMWA) commended the FDA for making another option available to women. AMWA stated that it believed mifepristone would go a long way to improve options for women in early pregnancy. The organization has since published a supplement to its Journal of the American Medical Women’s Association featuring articles educating readers about mifepristone. A copy of the supplement can be obtained by calling Melisa Marin at (703) 838-0500.
In the other camp sits Rock for Life. This group declares that the FDA’s decision has "escalated chemical warfare." (See www.rockforlife.org.)
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.